Jiangsu Hengrui
| Company type | listed company |
|---|---|
| SSE: 600276 | |
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Lianyungang, Jiangsu Shanghai, China |
Area served | China & global |
Key people | Sun Piaoyang (chairman) |
Number of employees | 24,500 (2020) |
| Website | www |
Jiangsu Hengrui Medicine Company Limited, also known as Jiangsu Hengrui Medicine, is a Chinese pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic (cancer) drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics.[1][2] It is the largest listed pharmaceutical company in China.[3]
The company history goes back to 1970. It was established in its current form in 1997 and headquartered in Lianyungang, Jiangsu. It was listed on Shanghai Stock Exchange in 2000.[4] The current headquarters is located in Shanghai and is the seat of the company CEO, several corporate functions and several R&D units. R&D units belonging to the company are located also in Beijing.
In 2020, the company established its clinical R&D organizations the USA (Princeton, New Jersey) and in Europe (Basel, Switzerland).[5][6] The Swiss-based Hengrui Europe Therapeutics AG company also hosts the discovery R&D units, with their focus on protein engineering and on the mRNA technology platform, respectively.
As of December 2020, the company was running ex-China clinical trials esp. in the field of anti-cancer drugs (i.e. anti-PD-1 immune checkpoint inhibitor camrelizumab[7] in hepatocellular carcinoma, a nonsteroidal antiandrogen rezvilutamide in prostate cancer,[8] a PARP inhibitor fluzoparib[9] in solid cancers esp. prostate cancer,[10] a VEGFR2 inhibitor apatinib as a combination therapy in various indications), in metabolic diseases (i.e. type II diabetes[11]), in autoimmune diseases (i.e. interleukin-17 receptor blocker vunakizumab in psoriasis), in HIV treatment and analgesia.
References
- ^ Profile of Jiangsu Hengrui Medicine Company Limited
- ^ "Search of: Hengrui - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-11-22.
- ^ China’s pharmaceutical industry is poised for major growth
- ^ Company Profile
- ^ "Hengrui Medicine sets up clinical research and development in Basel". Basel Area Business & Innovation. Retrieved 2020-11-22.
- ^ www.zefix.ch https://www.zefix.ch/en/search/entity/list/firm/1448748?name=hengrui&searchType=exact. Retrieved 2020-11-22.
{{cite web}}: Missing or empty|title=(help) - ^ "Search of: camrelizumab - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
- ^ "Search of: SHR-3680 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
- ^ "Search of: SHR-3162 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
- ^ "Search of: SHR-3162 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
- ^ Jiangsu HengRui Medicine Co., Ltd. (2020-12-09). "Evaluation of the Efficacy and Safety of INS068 Injection and Insulin Degludec Subcutaneous Injection Once Daily in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With One or Two Oral Antidiabetics (A Randomized, Open-Label, Two-Arm, Treat-to-Target, Parallel Controlled Trial)".
{{cite journal}}: Cite journal requires|journal=(help)
